Bristol-Myers, with partner Pfizer, is testing factor 10a blocker apixaban in a giant 15, 000-patient trial on preventing stroke.

FORBES: Magazine Article

The drugs work by blocking an enzyme called factor 10a that helps spur the production of a crucial clot-promoting protein called thrombin.

FORBES: Magazine Article